Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital: univariate and multivariate analyses.

Toshiro Okuyama, Takahiro Higashi, A. Edagawa, Shigeyuki Nagata, Kenkichi Hashimoto, Hiroshi Saeki, Eiji Oki, Hideaki Uchiyama, Hirofumi Kawanaka, Masaru Morita, Masahiro Tateishi, Daisuke Korenaga, Hidemichi Yaita, Kenji Takenaka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy. This study was based on the outcomes of 86 potentially curative patients who had undergone curability B resection of gastric cancer with or without the subsequent administration of oral 5-fluorouracil analogue. There were 21 patients who underwent surgery alone with no oral anti-cancer agents (group A) and 65 patients who were treated postoperatively, mainly with UFT (Tegafur and uracil; group B). This study compared the ten-year survival times of these two groups using univariate and multivariate analyses. The amount of UFT in group B was 354.2 +/- 122.0 mg and the administration period was 11.7 +/- 7.2 months. The backgrounds showed significantly more older patients in group A compared than group B (P = 0.0002). A univariate analysis showed the ten-year survival rate in group B to be higher than group A (P = 0.0079). A multivariate analysis showed that the postoperative administration of UFT was an independent factor associated with prolongation of survival times as well as the extent of lymph nodes metastasis and pathological stage (P = 0.0096). This study provided conventional evidence that postoperative administration of oral 5-fluorouracil analogue is associated with better long-term prognoses in patients undergoing curability B resection for gastric carcinoma.

Original languageEnglish
Pages (from-to)138-144
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume103
Issue number7
Publication statusPublished - Jan 1 2012

Fingerprint

Tegafur
Uracil
Public Hospitals
Adjuvant Chemotherapy
Stomach Neoplasms
Multivariate Analysis
Survival
Mouth Neoplasms
Fluorouracil
Oral Administration
Stomach
Survival Rate
Lymph Nodes
Neoplasm Metastasis
Carcinoma
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital : univariate and multivariate analyses. / Okuyama, Toshiro; Higashi, Takahiro; Edagawa, A.; Nagata, Shigeyuki; Hashimoto, Kenkichi; Saeki, Hiroshi; Oki, Eiji; Uchiyama, Hideaki; Kawanaka, Hirofumi; Morita, Masaru; Tateishi, Masahiro; Korenaga, Daisuke; Yaita, Hidemichi; Takenaka, Kenji.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 103, No. 7, 01.01.2012, p. 138-144.

Research output: Contribution to journalArticle

Okuyama, T, Higashi, T, Edagawa, A, Nagata, S, Hashimoto, K, Saeki, H, Oki, E, Uchiyama, H, Kawanaka, H, Morita, M, Tateishi, M, Korenaga, D, Yaita, H & Takenaka, K 2012, 'Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital: univariate and multivariate analyses.', Fukuoka igaku zasshi = Hukuoka acta medica, vol. 103, no. 7, pp. 138-144.
Okuyama, Toshiro ; Higashi, Takahiro ; Edagawa, A. ; Nagata, Shigeyuki ; Hashimoto, Kenkichi ; Saeki, Hiroshi ; Oki, Eiji ; Uchiyama, Hideaki ; Kawanaka, Hirofumi ; Morita, Masaru ; Tateishi, Masahiro ; Korenaga, Daisuke ; Yaita, Hidemichi ; Takenaka, Kenji. / Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital : univariate and multivariate analyses. In: Fukuoka igaku zasshi = Hukuoka acta medica. 2012 ; Vol. 103, No. 7. pp. 138-144.
@article{199f6ecfce4747cd8bb5c25323489bb5,
title = "Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital: univariate and multivariate analyses.",
abstract = "The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy. This study was based on the outcomes of 86 potentially curative patients who had undergone curability B resection of gastric cancer with or without the subsequent administration of oral 5-fluorouracil analogue. There were 21 patients who underwent surgery alone with no oral anti-cancer agents (group A) and 65 patients who were treated postoperatively, mainly with UFT (Tegafur and uracil; group B). This study compared the ten-year survival times of these two groups using univariate and multivariate analyses. The amount of UFT in group B was 354.2 +/- 122.0 mg and the administration period was 11.7 +/- 7.2 months. The backgrounds showed significantly more older patients in group A compared than group B (P = 0.0002). A univariate analysis showed the ten-year survival rate in group B to be higher than group A (P = 0.0079). A multivariate analysis showed that the postoperative administration of UFT was an independent factor associated with prolongation of survival times as well as the extent of lymph nodes metastasis and pathological stage (P = 0.0096). This study provided conventional evidence that postoperative administration of oral 5-fluorouracil analogue is associated with better long-term prognoses in patients undergoing curability B resection for gastric carcinoma.",
author = "Toshiro Okuyama and Takahiro Higashi and A. Edagawa and Shigeyuki Nagata and Kenkichi Hashimoto and Hiroshi Saeki and Eiji Oki and Hideaki Uchiyama and Hirofumi Kawanaka and Masaru Morita and Masahiro Tateishi and Daisuke Korenaga and Hidemichi Yaita and Kenji Takenaka",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "103",
pages = "138--144",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "7",

}

TY - JOUR

T1 - Ten-year survival of curability B gastric cancer patients treated by tegafur-uracil as postoperative adjuvant chemotherapy in a common public hospital

T2 - univariate and multivariate analyses.

AU - Okuyama, Toshiro

AU - Higashi, Takahiro

AU - Edagawa, A.

AU - Nagata, Shigeyuki

AU - Hashimoto, Kenkichi

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Uchiyama, Hideaki

AU - Kawanaka, Hirofumi

AU - Morita, Masaru

AU - Tateishi, Masahiro

AU - Korenaga, Daisuke

AU - Yaita, Hidemichi

AU - Takenaka, Kenji

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy. This study was based on the outcomes of 86 potentially curative patients who had undergone curability B resection of gastric cancer with or without the subsequent administration of oral 5-fluorouracil analogue. There were 21 patients who underwent surgery alone with no oral anti-cancer agents (group A) and 65 patients who were treated postoperatively, mainly with UFT (Tegafur and uracil; group B). This study compared the ten-year survival times of these two groups using univariate and multivariate analyses. The amount of UFT in group B was 354.2 +/- 122.0 mg and the administration period was 11.7 +/- 7.2 months. The backgrounds showed significantly more older patients in group A compared than group B (P = 0.0002). A univariate analysis showed the ten-year survival rate in group B to be higher than group A (P = 0.0079). A multivariate analysis showed that the postoperative administration of UFT was an independent factor associated with prolongation of survival times as well as the extent of lymph nodes metastasis and pathological stage (P = 0.0096). This study provided conventional evidence that postoperative administration of oral 5-fluorouracil analogue is associated with better long-term prognoses in patients undergoing curability B resection for gastric carcinoma.

AB - The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy. This study was based on the outcomes of 86 potentially curative patients who had undergone curability B resection of gastric cancer with or without the subsequent administration of oral 5-fluorouracil analogue. There were 21 patients who underwent surgery alone with no oral anti-cancer agents (group A) and 65 patients who were treated postoperatively, mainly with UFT (Tegafur and uracil; group B). This study compared the ten-year survival times of these two groups using univariate and multivariate analyses. The amount of UFT in group B was 354.2 +/- 122.0 mg and the administration period was 11.7 +/- 7.2 months. The backgrounds showed significantly more older patients in group A compared than group B (P = 0.0002). A univariate analysis showed the ten-year survival rate in group B to be higher than group A (P = 0.0079). A multivariate analysis showed that the postoperative administration of UFT was an independent factor associated with prolongation of survival times as well as the extent of lymph nodes metastasis and pathological stage (P = 0.0096). This study provided conventional evidence that postoperative administration of oral 5-fluorouracil analogue is associated with better long-term prognoses in patients undergoing curability B resection for gastric carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84868657616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868657616&partnerID=8YFLogxK

M3 - Article

C2 - 22978066

AN - SCOPUS:84868657616

VL - 103

SP - 138

EP - 144

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 7

ER -